Point Nemo Capital’s Harmony Biosciences HRMY Stock Holding History

Point Nemo Capital’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-18,610	Closed	-$696K	–	105
2025 Q4	$696K	Buy	+18,610	New	+$612K	0.69%	67

Other funds holding HRMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Point Nemo Capital's HRMY Position: Q1 2026 in Review

Point Nemo Capital sold out of Harmony Biosciences (HRMY) in Q1 2026, closing a stake of 18,610 shares — an estimated $696K sold.

Point Nemo Capital first reported a position in HRMY in Q4 2025 and held it in 1 quarter. The position peaked at $696K in Q4 2025. 310 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

Point Nemo Capital reported no remaining Harmony Biosciences position as of Q1 2026 after selling out during the quarter.
Point Nemo Capital sold 18,610 Harmony Biosciences shares in Q1 2026, an estimated $696K.
Point Nemo Capital first reported a position in Harmony Biosciences in Q4 2025 and held it in 1 quarter.
Point Nemo Capital's Harmony Biosciences position peaked at $696K in Q4 2025.
310 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Point Nemo Capital's 13F filing for Q1 2026, filed 15 May 2026.